 Aerie Pharmaceuticals, Inc. NASDAQ:AERI, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today announced that Peter J. McDonnell, M.D., has been appointed to the Companys Board of Directors and will also be a member of both the Nominating and Corporate Governance and Compensation Committees of the Board. 